Patents by Inventor Paul J. Coleman

Paul J. Coleman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080287414
    Abstract: The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 27, 2005
    Publication date: November 20, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Chunze Li, Lou Anne Neilson, Christy M. Olson, Edward S. Tasber
  • Publication number: 20080262046
    Abstract: The present invention is directed to amidopropoxyphenyl compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: April 10, 2006
    Publication date: October 23, 2008
    Inventors: Paul J. Coleman, John Schreier
  • Patent number: 7427637
    Abstract: The present invention relates to bicyclic dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: September 23, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, Lou Anne Neilson
  • Publication number: 20080207693
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 28, 2008
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Publication number: 20080199459
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: August 11, 2004
    Publication date: August 21, 2008
    Inventors: Paul J. Coleman, Christopher D. Cox
  • Publication number: 20080194582
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 14, 2008
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Publication number: 20080182843
    Abstract: The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: February 6, 2006
    Publication date: July 31, 2008
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Lou Anne Neilson, David B. Whitman
  • Publication number: 20080139586
    Abstract: The present invention relates to fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: January 13, 2006
    Publication date: June 12, 2008
    Inventors: Paul J. Coleman, George D. Hartman
  • Publication number: 20080132490
    Abstract: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: November 30, 2007
    Publication date: June 5, 2008
    Inventors: Jeffrey M. Bergman, Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Swati P. Mercer, Anthony J. Roecker
  • Publication number: 20080102068
    Abstract: The present invention relates to fluorinated 2-aminomethylthienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: January 13, 2006
    Publication date: May 1, 2008
    Inventors: Paul J. Coleman, George D. Hartman
  • Patent number: 7348440
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Paul J. Coleman, Christopher D. Cox, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, William F. Hoffman, Edward S. Tasber
  • Patent number: 7307085
    Abstract: The present invention relates to bicyclic tetrahydropyridine compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: December 11, 2007
    Assignee: Merck & Co., Inc.
    Inventor: Paul J. Coleman
  • Patent number: 7294640
    Abstract: The present invention relates to substituted thiazole derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin and MCAK activity, and for inhibiting KSP kinesin and MCAK. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: November 13, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Paul J. Coleman, Robert M. Garbaccio, Lou Anne Neilson
  • Patent number: 7235580
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: June 26, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Brenda J. Mariano
  • Patent number: 7196076
    Abstract: Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and/or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: March 27, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Paul J. Coleman, Lou Anne Neilson
  • Patent number: 7109191
    Abstract: The present invention relates to novel benzazepinone derivatives, their synthesis, and their use as ?v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors ?v?3 and ?v?5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: September 19, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Meissner, Paul J. Coleman, Mark E. Duggan, George D. Hartman, Jiabing Wang, John H. Hutchinson
  • Publication number: 20040198717
    Abstract: Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and/or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.
    Type: Application
    Filed: April 16, 2004
    Publication date: October 7, 2004
    Inventors: Paul J Coleman, Lou Anne Neilson
  • Patent number: 6784190
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: August 31, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, George D. Hartman, Cecilia A. Hunt, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Garry R. Smith, Jiabing Wang
  • Publication number: 20040142919
    Abstract: The present invention relates to novel benzazepinone derivatives, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 22, 2004
    Inventors: Robert S. Meissner, Paul J. Coleman, Mark E. Duggan, George D. Hartman, Jiabing Wang, John H. Hutchinson
  • Publication number: 20020040030
    Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R═H or Me), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
    Type: Application
    Filed: September 14, 2001
    Publication date: April 4, 2002
    Inventors: Paul J. Coleman, Donghui Cui, Mark E. Duggan, John H. Hutchinson, Thomayant Prueksaritanont, Maria Victoria Silva Elipe, Xiaojun Fang